Regencell Bioscience Limited’s (NASDAQ:RGC) stock is an undiscovered short squeeze potential. The short volume ratio has similar pattern as that of GameStop Corp. (NYSE:GME), whereby both averaged over 40% in the past year. In fact, RGC is more heavily shorted than GME as some days were close to 90% shorted.
However, as much as RGC and GME stock’s short volume profile is similar, not much is known about the facts and figures of RGC, which is provided below. As of 16 May 2022, RGC’s founder and CEO holds 10,539,159 ordinary shares, representing 81.0% of the total number of issued and outstanding ordinary shares in RGC. RGC’s total cumulative short volume as reported by third party data analytics provider is over 19 million shares and RGC’s total reported short volume to outstanding shares (excluding CEO and Chairman ownership ratio) is over 7 times, which is almost double that of GME. Where are all the extra shares coming from?
provider is over 19 million shares and RGC’s total reported short volume to outstanding shares (excluding CEO and Chairman ownership ratio) is over 7 times, which is almost double that of GME. Where are all the extra shares coming from?
(i) FINRA data from https://stocksera.pythonanywhere.com/
(ii) Exchange data from Futubull
(iii) Insiders (CEO and Former CEO) data from the latest schedule 14A and 13D filings
“Too often, sophisticated hedge funds have used short selling and complex derivatives to take advantage of small investors. They will short a company, conduct a negative publicity campaign to drive the stock price down temporarily and cash out, then do it all over again many times. The term for this, as you may be aware, is ‘short & distort,’” Elon Musk wrote in his email exchange to CNBC.
As witnessed on Reddit and other social media and forums, especially during the GME short squeeze, retail shareholders came together, driven by the community’s effort to punish market participants who make a living shorting and distorting public companies, causing them to stumble and fall.
GME’s 3-year historical stock chart, net loss and net cash position at its financial year ended 2019 to 2022 are as follows:-
|Financial year ended
|Net Profit/(Loss) ($ million)
|Net cash ($ million)
|30 January 2019
|30 January 2020
|30 January 2021
|30 January 2022
Source: Capital IQ
A short squeeze on GME created a return of 51x (current price to its historical low) to 191x (historical high to its historical low), what is the potential for RGC if there is a short squeeze?
Founder & CEO’s Conviction Of A Better And Brighter Future
When insiders (and in the case of RGC, its CEO) have consistently bought shares of the company, it demonstrates their confidence and belief in the company.
Since the listing of RGC on Nasdaq on 16 July 2021, RGC’s CEO has purchased over $5 million of ordinary shares and has not sold any shares. Such percentage of shareholding also gives confidence to investors and potential investors alike as it is apparent the CEO is confident about the future of the company.
The CEO is literally putting his money where his mouth is and he will continue to use his personal funds to purchase company shares to demonstrate his commitment and confidence to the Company and his position against short and distort sellers. To date, the CEO:-
Short sellers may not have noticed or have overlooked this important shareholder composition. The company is backed by strong shareholders, e.g., Samuel Chen and Fiona Chang, directors and shareholders of Digital Mobile Ventures Ltd.
Samuel Chen was very successful alongside Li Ka-shing from his early investment in Zoom. He owned 8.8% of the total voting power in Zoom post-IPO and Zoom’s market capitalization peaked at US$161 billion on 19 October 2020.
Based on Schedule 13G filing with the SEC on 15 December 2021, Digital Mobile Ventures Ltd. is the second largest shareholder in RGC, holding approximately 7.63% of the total outstanding shares.
Following the announcement on 16 February 2022 of its investigational liquid-formula RGC-COV19TM showing effectiveness in eliminating mild to moderate COVID-19 symptoms within a 6-day treatment
period through the Company’s EARTH efficacy trial, the Company has recently announced on 18 May 2022 that its additional efficacy trial corroborated the data of the first efficacy trial. In delivering natural treatment that are safe and effective, the company is clearly in the right direction to save and improve lives of patients, which result in a positive impact and benefit to the people around them as well.
The company also recently announced that all directors and employees who were previously granted stock options upon the Company’s IPO have agreed to a further lock-up undertaking for a period of six months after their stock options become vested; as their stock options are set to vest on 16 July 2022, their shares will remain locked up until 16 January 2023.
When the economy heads toward a recession, it is natural for investors to worry about falling stock prices and its impact on their portfolios, and look towards recession-resistant stocks. During economic downturn like what we are experiencing now, smart money rotates into sectors that are less sensitive to the economic cycle, like healthcare, which have historically fared well during recessions. The simple reason is that health is always a priority and nothing else is more important.
RGC CEO is a strong shareholder and will continue to invest in the company with the goal of saving and improving the lives of patients, especially children.
Philanthropic project – helping people in need.
Regencell Foundation is a private philanthropic foundation established by RGC’s CEO in 2017. He is currently spearheading a philanthropic project to provide grants to over 10,000 children afflicted with ADHD, ASD, COVID-19 and those in severe financial conditions. RGC’s CEO started providing grants on 16 April 2022 and has helped over 150 children. Interested persons may see the company’s links below.
Source from: ValueWalk